LifeVantage Q3 Earnings Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy LFVN?
Source: seekingalpha
- Disappointing Earnings: LifeVantage reported a Q3 non-GAAP EPS of $0.12, missing expectations by $0.04, indicating a decline in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s Q3 revenue of $43.7 million represents a 25.2% year-over-year decrease, falling short of the anticipated $44.0 million, reflecting weakened market demand and increased competitive pressures.
- Adjusted FY 2026 Guidance: LifeVantage anticipates that its FY 2026 revenue, adjusted EBITDA, and adjusted earnings per share will be close to the lower end of its previously issued guidance, highlighting growing challenges and uncertainties facing the company.
- Tax Rate Expectations: The company expects a full-year tax rate of approximately 18% to 20%, which will impact future financial performance, particularly in the context of its international expansion and new product launches.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFVN
Wall Street analysts forecast LFVN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.020
Low
12.00
Averages
12.00
High
12.00
Current: 5.020
Low
12.00
Averages
12.00
High
12.00
About LFVN
LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LifeVantage Q3 Earnings Miss Expectations
- Disappointing Earnings: LifeVantage reported a Q3 non-GAAP EPS of $0.12, missing expectations by $0.04, indicating a decline in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s Q3 revenue of $43.7 million represents a 25.2% year-over-year decrease, falling short of the anticipated $44.0 million, reflecting weakened market demand and increased competitive pressures.
- Adjusted FY 2026 Guidance: LifeVantage anticipates that its FY 2026 revenue, adjusted EBITDA, and adjusted earnings per share will be close to the lower end of its previously issued guidance, highlighting growing challenges and uncertainties facing the company.
- Tax Rate Expectations: The company expects a full-year tax rate of approximately 18% to 20%, which will impact future financial performance, particularly in the context of its international expansion and new product launches.
See More
LifeVantage Appoints New CEO Terrence Moorehead Effective August 2026
- Executive Appointment: LifeVantage has appointed Terrence Moorehead as the new President and CEO, effective August 5, 2026, marking a significant leadership change aimed at driving future growth and innovation within the company.
- Succession Plan: Moorehead will succeed Steve Fife, who is set to retire on April 30, with Director Michael Beindorff serving as interim CEO during the transition, ensuring stable operations throughout this period.
- Board Membership: New CEO Moorehead will also join the LifeVantage board, a move that not only strengthens corporate governance but also provides robust leadership support for future strategic decisions.
- Market Reaction: This executive change may impact investor confidence, particularly as the company faces market challenges from GLP-1 hormone drugs and the integration of LoveBiome, with the future leadership direction likely to have profound implications for company performance.
See More
LifeVantage Appoints New CEO Terrence Moorehead
- New CEO Appointment: LifeVantage has appointed Terrence Moorehead as the new President and CEO, effective August 5, 2026, bringing over 25 years of leadership experience that is expected to revitalize the brand and accelerate customer growth.
- Retirement of Former CEO: Current CEO Steve Fife will retire on April 30, 2026, with Moorehead's appointment aimed at ensuring leadership stability during the transition, as Fife has significantly contributed to the company's transformation and financial health over the past nine years.
- Transition Leadership Team: Prior to Moorehead's start, the Board has appointed Michael Beindorff as Interim CEO to ensure continuity, with the interim team comprising experienced executives capable of effectively managing the company's operations during this period.
- Strategic Growth Potential: Moorehead expressed that LifeVantage's science-backed products and passionate consultant community create a strong foundation for future growth, with expectations to further enhance brand positioning and drive sustainable growth to deliver shareholder value.
See More
LIFEVANTAGE CORP NAMES TERRENCE MOOREHEAD PRESIDENT AND CEO STARTING AUGUST 5, 2026
- Leadership Change: LifeVantage Corporation has appointed Terrence Moorehead as the new President and CEO.
- Effective Date: The appointment will take effect on August 5, 2026.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
LifeVantage Q2 Earnings Report Analysis
- Earnings Performance: LifeVantage reported a Q2 non-GAAP EPS of $0.15, aligning with market expectations, yet revenue of $48.9 million fell short by $5.5 million, reflecting a significant 27.8% year-over-year decline that highlights substantial sales challenges for the company.
- Inventory Recovery: The company is working to recover from inventory stockouts, aiming to enhance future sales capabilities through improved supply chain management and inventory control, which could strengthen its competitive position in the market.
- Acquisition Impact: The acquisition of LoveBiome has affected the company's financial status; while it has not significantly boosted revenue in the short term, it may drive growth in the long term through product diversification.
- Market Reaction: Due to the revenue miss, investors are adopting a cautious stance on LifeVantage's future outlook, which may lead to stock price volatility and impact the company's performance in the capital markets.
See More
LifeVantage Q3 Earnings Miss Expectations
- Disappointing Earnings: LifeVantage reported a Q3 non-GAAP EPS of $0.12, missing expectations by $0.04, indicating a decline in profitability that may undermine investor confidence.
- Significant Revenue Decline: The company’s Q3 revenue of $43.7 million represents a 25.2% year-over-year decrease, falling short of the anticipated $44.0 million, reflecting weakened market demand and increased competitive pressures.
- Adjusted FY 2026 Guidance: LifeVantage anticipates that its FY 2026 revenue, adjusted EBITDA, and adjusted earnings per share will be close to the lower end of its previously issued guidance, highlighting growing challenges and uncertainties facing the company.
- Tax Rate Expectations: The company expects a full-year tax rate of approximately 18% to 20%, which will impact future financial performance, particularly in the context of its international expansion and new product launches.
See More
LifeVantage Appoints New CEO Terrence Moorehead Effective August 2026
- Executive Appointment: LifeVantage has appointed Terrence Moorehead as the new President and CEO, effective August 5, 2026, marking a significant leadership change aimed at driving future growth and innovation within the company.
- Succession Plan: Moorehead will succeed Steve Fife, who is set to retire on April 30, with Director Michael Beindorff serving as interim CEO during the transition, ensuring stable operations throughout this period.
- Board Membership: New CEO Moorehead will also join the LifeVantage board, a move that not only strengthens corporate governance but also provides robust leadership support for future strategic decisions.
- Market Reaction: This executive change may impact investor confidence, particularly as the company faces market challenges from GLP-1 hormone drugs and the integration of LoveBiome, with the future leadership direction likely to have profound implications for company performance.
See More
LifeVantage Appoints New CEO Terrence Moorehead
- New CEO Appointment: LifeVantage has appointed Terrence Moorehead as the new President and CEO, effective August 5, 2026, bringing over 25 years of leadership experience that is expected to revitalize the brand and accelerate customer growth.
- Retirement of Former CEO: Current CEO Steve Fife will retire on April 30, 2026, with Moorehead's appointment aimed at ensuring leadership stability during the transition, as Fife has significantly contributed to the company's transformation and financial health over the past nine years.
- Transition Leadership Team: Prior to Moorehead's start, the Board has appointed Michael Beindorff as Interim CEO to ensure continuity, with the interim team comprising experienced executives capable of effectively managing the company's operations during this period.
- Strategic Growth Potential: Moorehead expressed that LifeVantage's science-backed products and passionate consultant community create a strong foundation for future growth, with expectations to further enhance brand positioning and drive sustainable growth to deliver shareholder value.
See More
LIFEVANTAGE CORP NAMES TERRENCE MOOREHEAD PRESIDENT AND CEO STARTING AUGUST 5, 2026
- Leadership Change: LifeVantage Corporation has appointed Terrence Moorehead as the new President and CEO.
- Effective Date: The appointment will take effect on August 5, 2026.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
LifeVantage Q2 Earnings Report Analysis
- Earnings Performance: LifeVantage reported a Q2 non-GAAP EPS of $0.15, aligning with market expectations, yet revenue of $48.9 million fell short by $5.5 million, reflecting a significant 27.8% year-over-year decline that highlights substantial sales challenges for the company.
- Inventory Recovery: The company is working to recover from inventory stockouts, aiming to enhance future sales capabilities through improved supply chain management and inventory control, which could strengthen its competitive position in the market.
- Acquisition Impact: The acquisition of LoveBiome has affected the company's financial status; while it has not significantly boosted revenue in the short term, it may drive growth in the long term through product diversification.
- Market Reaction: Due to the revenue miss, investors are adopting a cautious stance on LifeVantage's future outlook, which may lead to stock price volatility and impact the company's performance in the capital markets.
See More
